Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT04466345 Recruiting - Clinical trials for Major Depressive Disorder

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Start date: October 6, 2021
Phase: Phase 2
Study type: Interventional

This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).

NCT ID: NCT04461327 Recruiting - Clinical trials for Major Depressive Disorder

Psychophysiological Study of Pain Perception in Depressed Patients With Suicidal Risk

R2D2
Start date: November 25, 2020
Phase: N/A
Study type: Interventional

Joiner's interpersonal theory of suicide postulates that the wish of death comes from feelings of perceived burdensomeness and thwarted belongingness. But, only people who have acquired the capability to kill themselves will attempt suicide. The acquired capability refers to a reduction of fear to death, and a higher pain tolerance. Indeed, to commit suicide involves to endure pain during the act. Thus, higher pain tolerance seems to be a necessary feature for suicidal act. Past studies have shown higher pain threshold and tolerance in suicidal patients, whatever the stimulus was (electric, thermic or mechanical), compared to patients without suicide history. Moreover, Caceda and colleagues demonstrated higher pain threshold in recent suicide attempters (suicidal act within 72h) compared with depressed patients. Five days after the initial evaluation, pain threshold of recent suicide attempters decreased to be similar to depressed patients with suicidal ideation. Therefore, it may exist a specific state during which the pain tolerance is increased. During this "hypoalgesic state" patients with suicidal ideation could attempt suicide to get relief from suffering. However, little is known about the specific mechanisms that are responsible for the higher pain threshold and tolerance in suicide attempters. Pain is a dynamic system that results from excitatory and inhibitory messages. The modification of one of these mechanisms could explain the higher tolerance in recent suicide attempters. Three of them are of particular interest: 1. The conditioned pain modulation (CPM) is a modulatory pain mechanism. CPM works through descending pathway that reaches the spinal cord and modulates pain processing from the first nociceptive synapse.In recent suicidal patients, an increase of the CPM could explain higher pain tolerance. 2. The "wind-up" mechanism is defined as the highest excitability of the second order nerve. Even if the stimulus remains stable, pain continuously raises. In recent suicide attempters, a reduction of this mechanism could explain higher pain tolerance. 3. The threshold of Aδ and C nociceptors. If a nociceptive fiber is less excitable than the other, it would explain higher pain threshold.

NCT ID: NCT04448431 Completed - Clinical trials for Major Depressive Disorder

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

VIVRE
Start date: June 18, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit

NCT ID: NCT04448327 Recruiting - Clinical trials for Major Depressive Disorder

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression

tVNS_MDD_Sex
Start date: January 29, 2021
Phase: N/A
Study type: Interventional

This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD). We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active or sham expiratory-gated tVNS during a functional magnetic resonance imaging (fMRI) session, with simultaneous mood and physiological assessments. We hypothesize that expiratory-gated tVNS will effectively modulate, in a sex-dependent manner, specific brainstem-cortical pathways of the stress circuitry and attenuate physiological deficits in MDD.

NCT ID: NCT04447430 Recruiting - Clinical trials for Major Depressive Disorder

Light Therapy to Improve Symptoms in Pregnant Women With Major Depressive Disorder

GZPHBLT
Start date: June 12, 2020
Phase: N/A
Study type: Interventional

This study will investigate the effectivenss of bright light therapy(10000 lux white)on pregnant women with major depression disorder.

NCT ID: NCT04441008 Not yet recruiting - Clinical trials for Major Depressive Disorder

Accelerated iTBS for Depression and Suicidality

RAPID
Start date: December 2025
Phase: N/A
Study type: Interventional

The overall objective of this current study is to evaluate the feasibility, safety, and tolerability of "high dose" aiTBS in psychiatric inpatient and outpatients with treatment-refractory unipolar, non-psychotic major depressive disorder, using patients receiving ECT as an active comparator. Developing a better understanding of the feasibility and tolerability of adapting this treatment to an acutely ill patient population could lead to huge breakthroughs for clinician decision-making and for the further optimization of brain stimulation depression protocols. The results of this study can help guide future confirmatory efficacy trials of high-dose aiTBS by providing a better understanding of how feasibility, safety and tolerability compare to ECT, as well as unforeseen challenges of its use.

NCT ID: NCT04437485 Completed - Depression Clinical Trials

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Start date: October 14, 2020
Phase: Phase 2
Study type: Interventional

This pilot randomized controlled trial seeks: (1) to determine the preliminary efficacy of our modernized collaborative care intervention for depression in improving the diabetes risk markers of hemoglobin A1c and insulin resistance and (2) to explore whether somatic depressive symptoms - i.e., hyperphagia (increased appetite/weight) and/or hypersomnia (increased sleep) - moderate the effect of the eIMPACT-DM intervention on diabetes risk markers.

NCT ID: NCT04430556 Active, not recruiting - Clinical trials for Major Depressive Disorder

Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

The objective of this transversal study is to determine if there is a difference in the volume of the hippocampus with the degree of anxiety.

NCT ID: NCT04425278 Recruiting - Clinical trials for Major Depressive Disorder

tDCS Intervention on Motivational Anhedonia of Major Depressive Disorder

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Study of tDCS intervention on motivational anhedonia of Major Depressive Disorder

NCT ID: NCT04423471 Withdrawn - Clinical trials for Major Depressive Disorder

Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis

INPSYDER
Start date: February 1, 2021
Phase:
Study type: Observational [Patient Registry]

Objectives: To identify peripheral neuroinflammatory markers in patients suffering from major depression or psoriasis in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and their change after specific treatments. Methodology: Observational prospective cohort study in patients diagnosed with major depression and patients with plaque psoriasis, who naturalistically undergo different treatments (systemic or biological for psoriasis, antidepressants for depression). Forty-one patients with major depression attending psychiatric consultations and 82 patients with psoriasis attending dermatology consultations at Hospital Universitari Germans Trias i Pujol aged 18 to 65 years old will be selected for inclusion. All of them will be assessed at baseline and after 4 months treatment through a series of demographic and clinical variables, psychiatric diagnosis, psychopathological scales and immunological and biochemical variables after blood draw for obtaining serum, peripheral blood mononuclear cell (PBMC) and extraction of total RNA. Investigators will analyze the correlation between immunological markers and affective and cognitive symptoms at baseline, as well as their variation after treatment. Subsequently, a bivariate comparative analysis will be carried out, where statistically significant or marginally significant variables associated with psychopathological variables will be used to construct a multivariate model of binary logistic regression.